Rxwire
In the news · 48h FDA 38 Eli Lilly 17 Roche 9 Merck & Co. (MSD) 7 Johnson & Johnson 4 AbbVie 3 AstraZeneca 3 Daiichi Sankyo 2
Trials & R&D · first seen yesterday, updated yesterday

Boehringer and Envisagenics to develop precision cancer therapies

2 outlets Boehringer Ingelheim

Boehringer Ingelheim and Envisagenics have entered into a research collaboration and option agreement aimed at validating tumour-specific targets for the development of precision therapies in solid tumours.

Summary from Pharmaceutical Technology.

Coverage 3 articles · 2 outlets

  1. Pharmaceutical Technology
    Boehringer and Envisagenics to develop precision cancer therapies
  2. Pharmaceutical Technology
    Boehringer and Envisagenics to develop precision cancer therapies in $1bn deal
  3. Pharmaceutical Business Review
    Boehringer and Envisagenics to develop precision cancer therapies